PHASE I TRIAL OF ALL-TRANS RETINOIC ACID IN COMBINATION WITH INTERFERON

全反式视黄酸与干扰素联合的 I 期试验

• 批准号: 3744066
• 负责人: KATHERINE K MATTHAY
• 金额: --
• 依托单位: UNIVERSITY OF CALIFORNIA, SAN FRANCISCO
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/3744066
• 关键词: clinical trials; combination cancer therapy; combination chemotherapy; drug administration rate /duration; drug interactions; drug screening /evaluation; human subject; human therapy evaluation; interferon alpha; neoplasm /cancer chemotherapy; neoplasm /cancer immunotherapy; neoplasm /cancer nutrition therapy; nutrition related tag; pediatric neoplasm /cancer; retinoate; vitamin therapy

A body of preclinical data has provided a strong rationale for evaluating the combination of IFN-alpha with retinoic acid. The two drugs have different mechanisms of action and, when used in combination, show enhanced activity in both adult and pediatric tumor cell lines. The current study will attempt to maintain plasma all-trans-RA concentrations over time by administering drug on an intermittent schedule of three consecutive days per week, repeated weekly.

大量的临床前数据为评价 IFN-α与视黄酸的组合。 这两种药物 不同的作用机制，当组合使用时，显示 在成人和儿童肿瘤细胞系中的活性增强。 的 目前的研究将试图维持血浆全反式-RA浓度 随着时间的推移，通过以三个周期的间歇时间表施用药物， 每周连续几天，每周重复。